Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference

Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire

SEATTLE, March 1, 2013

SEATTLE, March 1, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a
biopharmaceutical company committed to discovering, developing and
commercializing products focused on inflammation, bleeding and disorders of
the central nervous system, today announced that Gregory A. Demopulos, M.D.,
chairman and chief executive officer, is scheduled to present at the Cowen and
Company 33^rd Annual Health Care Conference next week. The presentation is
scheduled for 11:20 a.m. Eastern Time on Wednesday, March 6, 2013.

The presentation will be webcast. The live and archived webcasts can be
accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.



SOURCE Omeros Corporation

Website: http://www.omeros.com
Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org